ITGAX/CD11c Targeting to Eliminate Pro-inflammatory DAM in ALS

Target: ITGAX/CD11c Targeting Composite Score: 0.408 Price: $0.41 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Quality Report Card click to collapse
C
Composite: 0.408
Top 87% of 1402 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C Mech. Plausibility 15% 0.42 Top 88%
C Evidence Strength 15% 0.48 Top 72%
B+ Novelty 12% 0.72 Top 42%
D Feasibility 12% 0.32 Top 89%
D Impact 12% 0.38 Top 96%
C Druggability 10% 0.42 Top 75%
D Safety Profile 8% 0.28 Top 96%
D Competition 6% 0.28 Top 98%
C Data Availability 5% 0.48 Top 77%
C Reproducibility 5% 0.42 Top 83%
Evidence
4 supporting | 4 opposing
Citation quality: 0%
Debates
1 session C+
Avg quality: 0.50
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

Microglial subtypes in neurodegeneration — friend vs foe

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflammatory) and their distinct roles in AD, PD, and ALS. Identify pharmacological targets for shifting microglia toward protective phenotypes.

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

TREM2-APOE Axis Manipulation via APOE Lipidation for DAM Recruitment
Score: 0.685 | Target: TREM2-APOE
CX3CL1-CX3CR1 Mimetic Therapy for Neuroprotection
Score: 0.635 | Target: CX3CL1-CX3CR1 Mimetic
CD38 Inhibition for NAD+ Restoration and Microglial Senescence Prevention
Score: 0.575 | Target: CD38
CSF1R Partial Agonism Combined with TREM2 Activation for ALS Neuroprotection
Score: 0.535 | Target: CSF1R Partial
PU.1 Degradation via PROTAC for Inflammatory Microglial Polarization
Score: 0.408 | Target: PU.1 Degradation via
IRP2-Iron Axis Modulation to Reduce Ferroptotic Vulnerability
Score: 0.398 | Target: IRP2-Iron

→ View full analysis & all 7 hypotheses

Description

NOT RECOMMENDED. Cell-type selectivity problem: CD11c is the canonical dendritic cell marker. Border-associated macrophages, meningeal DCs, and perivascular APCs all express CD11c. An ADC targeting CD11c would deplete these populations, impairing CNS immune surveillance. Mechanistic contradiction: PMID:30948433 shows TDP-43 drives CD11c+ expansion via TREM2, but TREM2 is hypothesized as protective—eliminating TREM2-activated cells is paradoxical. CD11c+ microglia in EAE show reparative signatures and may be required for remyelination.

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.42 (15%) Evidence 0.48 (15%) Novelty 0.72 (12%) Feasibility 0.32 (12%) Impact 0.38 (12%) Druggability 0.42 (10%) Safety 0.28 (8%) Competition 0.28 (6%) Data Avail. 0.48 (5%) Reproducible 0.42 (5%) KG Connect 0.50 (8%) 0.408 composite
8 citations 8 with PMID Validation: 0% 4 supporting / 4 opposing
For (4)
No supporting evidence
No opposing evidence
(4) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
7
1
MECH 7CLIN 0GENE 0EPID 1
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
CD11c+ microglia expand in ALS spinal cord and cor…SupportingMECH----PMID:30463021-
CD11c+ microglia show dual DAM-inflammation signat…SupportingEPID----PMID:29445926-
TDP-43 pathology drives CD11c+ microglial expansio…SupportingMECH----PMID:30948433-
Antibody-mediated cell depletion successfully targ…SupportingMECH----PMID:30374167-
CD11c is the canonical dendritic cell marker; ADC …OpposingMECH----PMID:Expert assessment-
CD11c+ microglia in EAE show reparative signatures…OpposingMECH----PMID:31988383-
If TDP-43 drives CD11c+ via TREM2, and TREM2 is pr…OpposingMECH----PMID:30948433-
No CD11c ADC exists for neurodegeneration; cell-ty…OpposingMECH----PMID:Expert assessment-
Legacy Card View — expandable citation cards

Supporting Evidence 4

CD11c+ microglia expand in ALS spinal cord and correlate with inflammation
CD11c+ microglia show dual DAM-inflammation signature distinct from CD11c- population
TDP-43 pathology drives CD11c+ microglial expansion via TREM2-dependent mechanism
Antibody-mediated cell depletion successfully targets microglia in vivo

Opposing Evidence 4

CD11c is the canonical dendritic cell marker; ADC would deplete meningeal/perivascular DCs
CD11c+ microglia in EAE show reparative signatures required for remyelination
If TDP-43 drives CD11c+ via TREM2, and TREM2 is protective, eliminating TREM2-activated cells is paradoxical
No CD11c ADC exists for neurodegeneration; cell-type selectivity unproven
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-18 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Therapeutic Hypotheses: Microglial Subtype Reprogramming in Neurodegeneration

Hypothesis 1: TREM2-APOE Axis Manipulation via APOE Sylation to Recruit Protective DAM in AD

Description: APOE4 impairs TREM2-dependent microglial clustering around amyloid plaques by disrupting lipid efflux pathways. Enhancing APOE lipidation through ABCA1 activation or inhibiting APOE fragmentation (by targeting cathepsin D) will restore TREM2-APOE signaling, promoting protective DAM recruitment to amyloid and increasing phagocytic clearance without driving neurotoxic inflammation.

**Target Gene/

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Microglial Subtype Reprogramming Hypotheses

Hypothesis 1: TREM2-APOE Axis Manipulation via APOE Sylation

Weaknesses in Evidence

Mechanistic Assumptions:
The hypothesis conflates correlation with causation regarding APOE4's effect on TREM2-dependent microglial function. The cited evidence (PMID:28445323) demonstrates TREM2 R47H impairs plaque localization, but this variant is distinct from APOE4 effects—APOE4 may influence microglial function through APOE-independent mechanisms.

APOE Fragmentation Complexity:
The assumption that cathepsin D inhibiti

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Critical Evaluation: Microglial Subtype Reprogramming Hypotheses

Practical Drug Development Assessment

Hypothesis 1: APOE Lipidation for DAM Recruitment

Target Druggability & Chemical Matter

ABCA1 (Strong tractability):

  • ABCA1 is a well-validated enzyme with clear substrate binding domains
  • Tool compounds: GW3965 (LXR agonist, Bristol-Myers Squibb), CS-6253 (ABCA1 agonist, scripps) — both increase ABCA1 expression
  • Failed programs: CSK-925323 (Pfizer) discontinued after hepatotoxicity signal from LXR-driven lipogenesis
  • Current clinical candidates: No

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.400.410.42 0.43 0.39 2026-04-252026-04-252026-04-25 Market PriceScoreevidencedebate 1 events
7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
1

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (6)

Paper:29445926
No extracted figures yet
Paper:30374167
No extracted figures yet
Paper:30463021
No extracted figures yet
Paper:30948433
No extracted figures yet
Paper:31988383
No extracted figures yet
Paper:Expert assessment
No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Microglial subtypes in neurodegeneration — friend vs foe — Analysis Notebook
→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
31.7th percentile (747 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
0

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.458

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

KG Entities (20)

ABCA1APOEAPOE4CD38CSF1RCX3CL1CX3CR1DAM subsetFTH1IREB2/IRP2ITGAX/CD11cNAD+NLRP3 inflammasomeP2Y12SPI1/PU.1TREM2TREM2-dependent clusteringTYROBPiron accumulationmicroglial survival

Related Hypotheses

LPS-TLR4-NF-κB Signaling Cascade as Therapeutic Target
Score: 7.200 | neurodegeneration
Enteric Nervous System Dysfunction as Self-Reinforcing Pathological Loop
Score: 7.000 | neurodegeneration
Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propagation
Score: 6.000 | neurodegeneration
SCFA Deficiency Disrupts Microglial Homeostasis and Promotes Neurodegeneration
Score: 5.500 | neurodegeneration
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (12 edges)

coordinates (1)

TREM2iron accumulation

depletes (1)

CD38NAD+

engages (1)

CX3CL1CX3CR1

impairs (1)

APOE4TREM2-dependent clustering

lipidates (1)

ABCA1APOE

maintains (1)

CSF1Rmicroglial survival

marks (1)

ITGAX/CD11cDAM subset

regulates (2)

CX3CR1P2Y12SPI1/PU.1TREM2

represses (1)

IREB2/IRP2FTH1

signals through (1)

TREM2TYROBP

suppresses (1)

CX3CR1NLRP3 inflammasome

Mechanism Pathway for ITGAX/CD11c Targeting

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    TREM2["TREM2"] -->|signals through| TYROBP["TYROBP"]
    APOE4["APOE4"] -->|impairs| TREM2_dependent_clusterin["TREM2-dependent clustering"]
    ABCA1["ABCA1"] -->|lipidates| APOE["APOE"]
    CX3CR1["CX3CR1"] -.->|suppresses| NLRP3_inflammasome["NLRP3 inflammasome"]
    CX3CR1_1["CX3CR1"] -->|regulates| P2Y12["P2Y12"]
    CD38["CD38"] -->|depletes| NAD_["NAD+"]
    CSF1R["CSF1R"] -->|maintains| microglial_survival["microglial survival"]
    SPI1_PU_1["SPI1/PU.1"] -->|regulates| TREM2_2["TREM2"]
    IREB2_IRP2["IREB2/IRP2"] -->|represses| FTH1["FTH1"]
    ITGAX_CD11c["ITGAX/CD11c"] -->|marks| DAM_subset["DAM subset"]
    TREM2_3["TREM2"] -->|coordinates| iron_accumulation["iron accumulation"]
    CX3CL1["CX3CL1"] -->|engages| CX3CR1_4["CX3CR1"]
    style TREM2 fill:#ce93d8,stroke:#333,color:#000
    style TYROBP fill:#ce93d8,stroke:#333,color:#000
    style APOE4 fill:#ce93d8,stroke:#333,color:#000
    style TREM2_dependent_clusterin fill:#4fc3f7,stroke:#333,color:#000
    style ABCA1 fill:#ce93d8,stroke:#333,color:#000
    style APOE fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1 fill:#ce93d8,stroke:#333,color:#000
    style NLRP3_inflammasome fill:#4fc3f7,stroke:#333,color:#000
    style CX3CR1_1 fill:#ce93d8,stroke:#333,color:#000
    style P2Y12 fill:#ce93d8,stroke:#333,color:#000
    style CD38 fill:#ce93d8,stroke:#333,color:#000
    style NAD_ fill:#ce93d8,stroke:#333,color:#000
    style CSF1R fill:#ce93d8,stroke:#333,color:#000
    style microglial_survival fill:#4fc3f7,stroke:#333,color:#000
    style SPI1_PU_1 fill:#4fc3f7,stroke:#333,color:#000
    style TREM2_2 fill:#ce93d8,stroke:#333,color:#000
    style IREB2_IRP2 fill:#ce93d8,stroke:#333,color:#000
    style FTH1 fill:#ce93d8,stroke:#333,color:#000
    style ITGAX_CD11c fill:#ce93d8,stroke:#333,color:#000
    style DAM_subset fill:#4fc3f7,stroke:#333,color:#000
    style TREM2_3 fill:#ce93d8,stroke:#333,color:#000
    style iron_accumulation fill:#4fc3f7,stroke:#333,color:#000
    style CX3CL1 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_4 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 ITGAX — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for ITGAX structures...
Querying Protein Data Bank API

Source Analysis

Microglial subtypes in neurodegeneration — friend vs foe

neurodegeneration | 2026-04-17 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)